14-day Premium Trial Subscription Try For FreeTry Free

Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of APRE
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Aprea Therapeutics Inc. stock price ended at $5.17 on Tuesday, after losing 1.71%.
(Updated on May 07, 2024)

Sell candidate since Apr 24, 2024 PDF

The Aprea Therapeutics Inc. stock price fell by -1.71% on the last day (Tuesday, 7th May 2024) from $5.26 to $5.17. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 3.48% from a day low at $5.17 to a day high of $5.35. The price has fallen in 6 of the last 10 days and is down by -3.72% for this period. Volume has increased on the last day by 2 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 5 thousand shares were bought and sold for approximately $26.56 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -20.01% during the next 3 months and, with a 90% probability hold a price between $3.26 and $5.67 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

APRE Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, April 29, 2024, and so far it has risen 1.69%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Aprea Therapeutics Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $5.24 and $5.83. A break-up above any of these levels will issue buy signals. Aprea Therapeutics Inc. gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Aprea Therapeutics Inc. stock

Aprea Therapeutics Inc. finds support from accumulated volume at $5.12 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.180 between high and low, or 3.48%. For the last week, the stock has had daily average volatility of 2.44%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (APRE) For The Upcoming Trading Day Of Wednesday 8th

For the upcoming trading day on Wednesday, 8th we expect Aprea Therapeutics Inc. to open at $5.23, and during the day (based on 14 day Average True Range), to move between $4.83 and $5.51, which gives a possible trading interval of +/-$0.344 (+/-6.66%) up or down from last closing price. If Aprea Therapeutics Inc. takes out the full calculated possible swing range there will be an estimated 13.32% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $5.12 (0.97%) than the resistance at $6.16 (19.15%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Aprea Therapeutics Inc. stock A Buy?

Aprea Therapeutics Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -3.875 Sell Candidate Unchanged

Predicted Opening Price for Aprea Therapeutics Inc. of Wednesday, May 8, 2024

Fair opening price May 8, 2024 Current price
$5.23 ( 1.16%) $5.17

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for APRE

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 5.41 4.64 %
R2 5.34 3.31 %
R1 5.30 2.49 %
Current price: 5.17
Support S1 5.16 -0.169 %
S2 5.12 -0.99 %
S3 5.05 -2.32 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 6.35 22.82 %
R2 6.19 19.73 %
R1 6.16 19.15 %
Current price 5.17
Support S1 5.12 -0.97%
S2 5.10 -1.35%
S3 5.08 -1.66%

FAQ

What is the symbol for Aprea Therapeutics Inc. Stock and on which exchange is it traded?
The symbol for Aprea Therapeutics Inc. is APRE and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Aprea Therapeutics Inc. Stock?
Aprea Therapeutics Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Aprea Therapeutics Inc. Stock?
Aprea Therapeutics Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Aprea Therapeutics Inc. Stock.

What's the current price of Aprea Therapeutics Inc. Stock?
As of the end of day on the May 07, 2024, the price of an Aprea Therapeutics Inc. (APRE) share was $5.17.

What is the 52-week high and low for Aprea Therapeutics Inc. Stock?
The 52-week high for Aprea Therapeutics Inc. Stock is $119.11 and the 52-week low is $21.41.

What is the market capitalization of Aprea Therapeutics Inc. Stock?
As of the May 07, 2024, the market capitalization of Aprea Therapeutics Inc. is 28.563M.

When is the next earnings date for Aprea Therapeutics Inc.?
The upcoming earnings date for Aprea Therapeutics Inc. is May 20, 2024.
Click to get the best stock tips daily for free!

About Aprea Therapeutics Inc.

Aprea Therapeutics. Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATR... APRE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT